Kareem has more than ten years of experience building partnerships and executing a range of deals, including transformative collaborations and acquisitions, in the cell and gene therapy space. He is responsible for business and corporate development as ElevateBio creates and operates a portfolio of cell and gene therapy companies to develop life-transforming medicines for patients.
Prior to ElevateBio, Kareem was Head of Business Development and Corporate Strategy at Evelo Biosciences. He played an integral role in the company’s $85 million initial public offerings (IPO) and private Series B and C fundraising rounds, helping to raise over $200 million. While at Celgene, he executed over a dozen deals with a total value greater than $5 billion and actively partnered with the science team to develop a cancer immunotherapy strategy which ultimately guided Celgene into the rapidly developing field of immuno-oncology (IO). He also led the B-cell maturation antigen (BCMA) collaboration with bluebird bio and the $1 billion, 10-year collaboration with Juno Therapeutics, focused on Chimeric Antigen Receptor Technology (CAR-T) and T-cell Receptor (TCR) technologies. Kareem started his career at Vertex Pharmaceuticals in formulation development.
Kareem graduated magna cum laude with a degree in Chemical Engineering from Brown University and received his MBA from Harvard Business School.